Development of platform technologies for antisense oligonucleotide-based therapeutics by a combination of nucleic acids chemistry and information sciences

2015 Fiscal Year Final Research Report

• Project/Area Number: 24249007
• Research Category: Grant-in-Aid for Scientific Research (A)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Drug development chemistry
• Research Institution: Osaka University
• Principal Investigator: Satoshi Obika 大阪大学, 薬学研究科(研究院), 教授 (80243252)
• Co-Investigator(Kenkyū-buntansha): KODAMA Tetsuya 名古屋大学, 大学院創薬科学研究科, 准教授 (00432443)
• Co-Investigator(Renkei-kenkyūsha): TAKAGI Tatsuya 大阪大学, 大学院薬学研究科, 教授 (80144517) ; MORIHIRO Kunihiko 医薬基盤研究所, 研究員 (70713890) ; KAWASHITA Norihito 大阪大学, 大学院薬学研究科, 助教 (00423111)
• Project Period (FY): 2012-05-31 – 2016-03-31
• Keywords: 核酸医薬 / ゲノム創薬 / アンチセンス核酸

Outline of Final Research Achievements

Promoting research focused on four issues in the antisense medicine and obtained the following results. An accurate qualitative sequence prediction model program of the antisense molecule was constructed. Syntheses of three types of nucleic acid monomers designed on different concepts were succeeded in. Attention points in the synthesis of oligonucleotides with the artificial nucleic acid monomer were revealed. A cellular uptake, especially on unusual tissue, of oligonucleotides was promoted by conjugating a bioactive synthetic compound.

Free Research Field

核酸医薬、生体関連科学